mitomycin C drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (8)
Papers in which this entity is mentioned.
- A Compendium of Mutational Signatures of Environmental Agents. (2019)
- EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. (2018)
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. (2017)
- Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. (2014)
- Involvement of p53 in the repair of DNA double strand breaks: multifaceted Roles of p53 in homologous recombination repair (HRR) and non-homologous end joining (NHEJ). (2014)
- Patient-derived tumour xenografts as models for oncology drug development. (2012)
- 3' end mRNA processing: molecular mechanisms and implications for health and disease. (2008)
- MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. (2008)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| mitomycin c | drug | 12 | 19 |
| mitomycin c (sigma) | drug | — | — |